New drug reduces protein in urine for patients with IgA nephropathy
A phase 3 trial shows povetacicept significantly lowers urinary protein and galactose-deficient IgA1 levels.
A drug called povetacicept reduced protein in the urine of people with IgA nephropathy. In a trial, the 24-hour urinary protein-to-creatinine ratio decreased by with povetacicept. The placebo group saw only a decrease by week 36.
Researchers conducted a phase 3, double-blind, placebo-controlled trial. Participants with biopsy-proven IgA nephropathy were assigned to receive povetacicept or a placebo. The drug was given subcutaneously every 4 weeks.
The drug is an enhanced, variant transmembrane activator and calcium-modulator and cyclophilin-ligand interactor (TACI)-Fc fragment fusion therapeutic. It is engineered for dual inhibition of BAFF and APRIL. BAFF and APRIL are proteins that play roles in IgA-producing B-cell populations.
Galactose-deficient IgA1 levels decreased by with povetacicept. Among participants with baseline hematuria, resolution occurred in with povetacicept and with placebo. The incidence of serious adverse events was for povetacicept and for placebo.
Key facts
- The 24-hour urinary protein-to-creatinine ratio decreased by with povetacicept.
- Galactose-deficient IgA1 levels decreased by with povetacicept.
- Resolution of hematuria occurred in of povetacicept participants with baseline hematuria.